Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50% — Live Feedhttps://www.live-feeds.com/feed/genmab-stock-surges-to-record-high-as-cancer-drug-slashes-risk-of-death-by-50Continuously updated, source-cited coverage. Genmab Stock Hits Record High After Phase 3 Cancer Trial Successhttps://www.live-feeds.com/feed/genmab-stock-surges-to-record-high-as-cancer-drug-slashes-risk-of-death-by-50https://www.live-feeds.com/feed/genmab-stock-surges-to-record-high-as-cancer-drug-slashes-risk-of-death-by-50#u172228Tue, 03 Nov 2026 12:56:07 +0000Genmab shares surged to an all-time high following a successful phase 3 clinical trial for its experimental cancer drug petosemtamab. When combined with Merck's therapy Keytruda, the bispecific treatment cut the risk of death by 50 percent compared to Keytruda alone in head and neck cancer patients. The positive readout triggered an eight billion dollar market valuation jump for Genmab. Financial analysts characterized the trial results as an exceedingly positive early survival win and a hat trick for the drugmaker.Why it mattersThe successful trial validates a major acquisition strategy